These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26980242)

  • 1. Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.
    Tamaoki S; Suzuki H; Okada M; Fukui N; Isobe M; Saito T
    Eur J Pharmacol; 2016 May; 779():168-76. PubMed ID: 26980242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperammonemic coma after hepatectomy in germ-free rats.
    Schalm SW; van der Mey T
    Gastroenterology; 1979 Aug; 77(2):231-4. PubMed ID: 447036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for hyperammonemia.
    Hadjihambi A; Khetan V; Jalan R
    Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hyperammonemia in liver failure.
    Jover-Cobos M; Khetan V; Jalan R
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
    Pedretti G; Calzetti C; Missale G; Fiaccadori F
    Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of lactitol (NS-4) on the increase in blood and brain ammonia concentration and on coma in newly developed rat models of hepatic coma].
    Watanabe M; Ozaki T; Hirata Y; Yoshikuni Y; Kimura K
    Nihon Yakurigaku Zasshi; 1995 Feb; 105(2):97-109. PubMed ID: 7737597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
    Jamshidzadeh A; Heidari R; Abasvali M; Zarei M; Ommati MM; Abdoli N; Khodaei F; Yeganeh Y; Jafari F; Zarei A; Latifpour Z; Mardani E; Azarpira N; Asadi B; Najibi A
    Biomed Pharmacother; 2017 Feb; 86():514-520. PubMed ID: 28024286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat.
    Therrien G; Rose C; Butterworth J; Butterworth RF
    Hepatology; 1997 Mar; 25(3):551-6. PubMed ID: 9049197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual evoked potentials in a rabbit model of hepatic encephalopathy. II. Comparison of hyperammonemic encephalopathy, postictal coma, and coma induced by synergistic neurotoxins.
    Pappas SC; Ferenci P; Schafer DF; Jones EA
    Gastroenterology; 1984 Mar; 86(3):546-51. PubMed ID: 6693016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms, diagnosis and management of hepatic encephalopathy.
    Prakash R; Mullen KD
    Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):515-25. PubMed ID: 20703237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy.
    Rodrigo R; Cauli O; Gomez-Pinedo U; Agusti A; Hernandez-Rabaza V; Garcia-Verdugo JM; Felipo V
    Gastroenterology; 2010 Aug; 139(2):675-84. PubMed ID: 20303348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinolinate in brain and cerebrospinal fluid in rat models of congenital hyperammonemia.
    Robinson MB; Heyes MP; Anegawa NJ; Gorry E; Djali S; Mellits ED; Batshaw ML
    Pediatr Res; 1992 Oct; 32(4):483-8. PubMed ID: 1279510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hepatic encephalopathy: role of rifaximin.
    Zeneroli ML; Avallone R; Corsi L; Venturini I; Baraldi C; Baraldi M
    Chemotherapy; 2005; 51 Suppl 1():90-5. PubMed ID: 15855752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats.
    Vogels BA; Maas MA; Daalhuisen J; Quack G; Chamuleau RA
    Hepatology; 1997 Apr; 25(4):820-7. PubMed ID: 9096582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Overt Hepatic Encephalopathy.
    Sussman NL
    Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.